SCHEMBL25985477

SCHEMBL25985477

CCNc1nc(Nc2cccc(S(C)(=O)=O)c2)nc(-c2cccc(C(F)F)n2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDH2 P48735 10/20 0.46
▸ IDH1 O75874 8/20 0.43
▸ CDK9 P50750 2/20 0.41
▸ CCNT1 O60563 1/20 0.41
▸ CCNE1 P24864 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ KDR P35968 2/20 0.41
▸ ABCB11 O95342 1/20 0.41
▸ ADORA3 P0DMS8 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ TBXA2R P21731 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ ADRA1A P35348 1/20 0.41
▸ OPRM1 P35372 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ AURKA O14965 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29560447 0.87 IDH1 (0.53) IDH2IDH1CDK9CCNT1CCNE1
SCHEMBL15102239 0.87 IDH1 (0.53) IDH2IDH1CDK9CCNT1CCNE1
SCHEMBL16388181 0.86 ROCK1 (0.47) IDH2IDH1CDK9CCNT1CCNE1
SCHEMBL15102421 0.77 IDH2 (0.58) IDH2IDH1KDRABCB11ADORA3
SCHEMBL16392199 0.77 TNNI3K (0.43) IDH2IDH1CCNE1CDK2ROCK1
SCHEMBL15102494 0.74 IDH1 (0.70) IDH2IDH1KDRABCB11ADORA3
SCHEMBL29763323 0.74 IDH1 (0.70) IDH2IDH1KDRABCB11ADORA3
SCHEMBL29560264 0.73 IDH1 (0.71) IDH2IDH1SYK
SCHEMBL15102434 0.73 IDH1 (0.71) IDH2IDH1SYK
SCHEMBL18520667 0.73 IDH1 (0.57) IDH2IDH1KDRABCB11ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2023-08-10 — — US disclosed
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2023-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT IDH2 110/4885IDH1 172/4885CDK9 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback